EyeGene Inc. (KOSDAQ:185490)
South Korea · Delayed Price · Currency is KRW 1,447.00
-13.00 (-0.89%)
At close: Apr 24, 2026
EyeGene Revenue
In the year 2025, EyeGene had annual revenue of 3.57B KRW with 6.29% growth. EyeGene had revenue of 774.00M in the quarter ending December 31, 2025, a decrease of -40.97%.
Revenue
3.57B
Revenue Growth
+6.29%
P/S Ratio
17.54
Revenue / Employee
n/a
Employees
n/a
Market Cap
62.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57B | 211.02M | 6.29% |
| Dec 31, 2024 | 3.36B | 230.37M | 7.37% |
| Dec 31, 2023 | 3.13B | -2.17B | -40.96% |
| Dec 31, 2022 | 5.29B | 2.05B | 63.27% |
| Dec 31, 2021 | 3.24B | -121.31M | -3.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 32.97B |
| Naturalendo Tech | 22.23B |
| NGeneBio | 21.24B |
| Ark Solutions | 16.08B |
| PanGen Biotech | 13.42B |
| ADBiotech | 12.90B |
| HLB Pep | 4.96B |
| Aptamer Sciences | 1.08B |